| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Nextech Crossover I GP S.a r.l. | 10% | $4,344,209 | 12,067,246 | Nextech Crossover I GP S.a. r.l. | 20 Dec 2024 | |||
| VANGUARD GROUP INC | 6.7% | $3,015,996 | 8,377,767 | The Vanguard Group | 31 Mar 2025 | |||
| BlackRock, Inc. | 3% | -53% | $1,103,358 | -$1,338,033 | 3,761,876 | -55% | BlackRock, Inc. | 30 Jun 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 2.9% | -68% | $1,286,757 | -$2,406,047 | 3,574,325 | -65% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2025 |
| Schonfeld Strategic Advisors LLC | 5.5% | +19% | $2,122,973 | -$41,906,118 | 273,579 | -95% | Schonfeld Strategic Advisors LLC | 30 Sep 2025 |
As of 30 Sep 2025, 5 institutional investors reported holding 55,398 shares of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN). This represents 1.1% of the company’s total 4,992,318 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 55,398 | $410,881 | -$31,452,222 | $7.76 | 5 |
| 2025 Q2 | 77,200,692 | $22,849,022 | -$3,437,337 | $0.30 | 80 |
| 2025 Q1 | 87,949,584 | $30,264,885 | -$35,777,339 | $0.34 | 109 |
| 2024 Q4 | 104,303,178 | $149,151,003 | -$24,954,008 | $1.43 | 129 |
| 2024 Q3 | 116,077,343 | $219,445,627 | +$3,272,056 | $1.89 | 115 |
| 2024 Q2 | 114,206,357 | $229,554,281 | -$23,968,075 | $2.01 | 120 |
| 2024 Q1 | 117,492,700 | $526,342,513 | +$23,958,185 | $4.48 | 124 |
| 2023 Q4 | 113,095,763 | $262,379,163 | +$21,039,242 | $2.32 | 104 |
| 2023 Q3 | 113,738,083 | $144,445,790 | -$76,640,644 | $1.27 | 127 |
| 2023 Q2 | 112,399,497 | $369,792,616 | +$12,845,282 | $3.29 | 145 |
| 2023 Q1 | 106,632,085 | $437,242,303 | +$17,660,953 | $4.11 | 156 |
| 2022 Q4 | 101,429,361 | $594,377,218 | +$41,420,886 | $5.86 | 150 |
| 2022 Q3 | 92,449,667 | $624,973,128 | +$39,050,654 | $6.76 | 147 |
| 2022 Q2 | 88,302,299 | $407,955,031 | +$36,774,738 | $4.62 | 121 |
| 2022 Q1 | 80,872,131 | $322,721,381 | +$33,055,220 | $3.99 | 127 |
| 2021 Q4 | 70,190,994 | $436,594,924 | -$9,658,535 | $6.22 | 120 |
| 2021 Q3 | 68,748,658 | $648,298,103 | -$40,839,729 | $9.43 | 108 |
| 2021 Q2 | 69,773,540 | $946,957,788 | -$9,186,549 | $13.58 | 129 |
| 2021 Q1 | 68,154,863 | $1,102,711,080 | -$36,197,720 | $16.18 | 130 |
| 2020 Q4 | 68,137,745 | $1,813,136,515 | +$51,864,511 | $26.61 | 147 |
| 2020 Q3 | 67,909,081 | $1,264,489,156 | +$48,626,981 | $18.62 | 132 |
| 2020 Q2 | 64,727,492 | $1,514,580,389 | +$684,777,923 | $23.40 | 129 |
| 2020 Q1 | 40,118,913 | $233,891,407 | +$26,078,897 | $5.83 | 82 |
| 2019 Q4 | 35,452,686 | $203,141,553 | -$5,999,927 | $5.73 | 69 |
| 2019 Q3 | 38,476,429 | $60,791,070 | -$6,777,200 | $1.58 | 73 |
| 2019 Q2 | 39,955,892 | $161,842,717 | +$11,993,581 | $4.05 | 77 |
| 2019 Q1 | 36,929,163 | $194,245,065 | +$104,832,192 | $5.26 | 65 |
| 2018 Q4 | 17,160,115 | $70,012,155 | -$10,222,226 | $4.08 | 48 |
| 2018 Q3 | 19,817,013 | $198,167,730 | +$76,403 | $10.00 | 46 |
| 2018 Q2 | 19,130,948 | $341,677,448 | +$7,606,792 | $17.86 | 52 |
| 2018 Q1 | 18,728,332 | $295,349,347 | +$23,699,944 | $15.77 | 56 |
| 2017 Q4 | 15,455,281 | $253,897,465 | -$4,017,344 | $16.43 | 45 |
| 2017 Q3 | 15,693,839 | $271,344,000 | +$10,576,212 | $17.29 | 40 |
| 2017 Q2 | 16,970,149 | $236,408,000 | +$236,408,000 | $13.97 | 29 |